Skip to main content
SpringerLink
Log in

Radioimmuntherapie

  • Chapter
Kompendium Internistische Onkologie

  • 156 Accesses

Zusammenfassung

Die Verwendung von monoklonalen Antikörpern als Träger für zytotoxische Reagenzien ist ein Konzept zur Verbesserung der Tumorbehandlung, das bereits Anfang des vorigen Jahrhunderts für Antiseren benutzt wurde.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Behr TM, Liersch T, Greiner-Bechert L et al (2002) Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94:1373–1381

    Article  PubMed  CAS  Google Scholar 

  • Buchsbaum DJ (1997) Experimental tumor targeting with radiolabeled ligands. Cancer 80:2371–2377

    Article  PubMed  CAS  Google Scholar 

  • Bunjes D, Buchmann I, Duncker C et al (2001) Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98(3):565–572

    Article  PubMed  CAS  Google Scholar 

  • DeNardo G, DeNardo SJ, Goldstein DS et al (1998) Maximum-tolerated dose, toxicity, and efficacy of 131-I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol 16:3246–3256

    PubMed  CAS  Google Scholar 

  • Forero-Torres A, Khazaeli MB, Carpenter M et al (2003) Phase I trial of intravenous 131I-HuCC49-CH2 in patients with metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 22:182

    Google Scholar 

  • Foss FM, Raubitscheck A, Mulshine JL et al (1998) Phase I study of the pharmacokinetics of an radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 4:2691–2700

    PubMed  CAS  Google Scholar 

  • Gopal AK, Gooley TA, Maloney DG et al (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stemcell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102:2351–2357

    Article  PubMed  CAS  Google Scholar 

  • Gopul AK, Rajendran JG, Petersdorf SH et al (2002) High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99(9):3158–3162

    Article  Google Scholar 

  • Grana C, Chinol M, Robertson C et al (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–212

    Article  PubMed  CAS  Google Scholar 

  • Hajjar G, Sharkey RM, Burton J et al (2002) Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14-anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2(1):21–42

    Article  Google Scholar 

  • Huston JS, George AJ (2001) Engineered antibodies take center stage. Hum Antibodies 10:127–142

    PubMed  CAS  Google Scholar 

  • Juweid MB, Swayne LC, Sharkey RM et al (1997) Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. Gynecol Oncol 67(3):259–271

    Article  PubMed  CAS  Google Scholar 

  • Kaminski MS, Estes J, Zasadny KR et al (2000) Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259–1266

    PubMed  CAS  Google Scholar 

  • Knox SJ, Goris ML, Tempero M et al (2000) Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 6(2):406–414

    PubMed  CAS  Google Scholar 

  • Leonhard JP, Coleman M, Kostakoglu L et al (2004). Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin’s lymphoma (NHL) (abstract). Proc Am Soc Clin Oncol 23:560

    Google Scholar 

  • Link B, Kaminski MS, Coleman M et al (2004). Phase II study of CVP followed by tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma (NHL) (abstract). Proc Am Soc Clin Oncol 23:560

    Google Scholar 

  • Liu SY, Eary JF, Peersdorf SH et al (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine 131-labeled anti-CD20 antibody and autologous stem cell rescue. J Clin Oncol 16:3270–3280

    PubMed  CAS  Google Scholar 

  • Matthews DC, Appelbaum FR, Eary JF et al (1999) 131I anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukaemia and myelodysplastic syndrome. Blood 94:1237–1247

    PubMed  CAS  Google Scholar 

  • Meredith RF, Alvarez RD, Partridge EE et al (2001) Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 16:305–315

    Article  PubMed  CAS  Google Scholar 

  • Nademanee A, Forman SJ, Molina A et al (2004) High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non Hodgkin’s lymphoma (NHL): Update of a phase I/II trial (abstract). Proc Am Soc Clin Oncol 23:557

    Google Scholar 

  • Nicholson S, Gooden CS, Hird V et al (1998) Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep 5(1):223–226

    PubMed  CAS  Google Scholar 

  • Press OW, Eary JF, Gooley T (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD-20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934–2942

    PubMed  CAS  Google Scholar 

  • Press OW, Unger JM, Braziel RM et al (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606–1612

    Article  PubMed  CAS  Google Scholar 

  • Riva P, Franceschi G, Arista A (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six year clinical experience. Cancer 80 (12suppl):2733–2742

    Article  PubMed  CAS  Google Scholar 

  • Schnell R, Dietlein M, Staak O et al (2002) Non-myeloablative radioimmunotherapy with a iodine-131-tagged anti-CD30 antibody (131J-Ki-4) in patients with refractory Hodkin’s lymphoma (abstract). Blood 100(1):203a

    Google Scholar 

  • Shipley DL, Spigel DR, Carrell DL et al (2004). Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial (abstract). Proc Am Soc Clin Oncol 23:560

    Google Scholar 

  • Storto G, Buchegger F, Waibel R et al (2001) Biokinetics of a F(abt)3 iodine-131-labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma. Cancer Biother Radiopharm 16:371–379

    Article  PubMed  CAS  Google Scholar 

  • Vriesendorp HM, Morton JD, Quadri SM (1995) Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin’s disease. Cancer Res 55(23 Suppl):5888s–5892s

    PubMed  CAS  Google Scholar 

  • Wahl RL, Zasadny KR, Estes J (2000) Single center experience with iodine 131I tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL) [abstract]. J Nucl Med 41(suppl):79

    Google Scholar 

  • Welt S, Scott AM, Divgi CR et al (1996) Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer: J Clin Oncol 14:1787–1797

    PubMed  CAS  Google Scholar 

  • Wiseman GA, Gordon LI, Multani PS et al (2002) Ibritumomab tiutexan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336–4342

    Article  PubMed  CAS  Google Scholar 

  • Witzig TE, Emmanoullides C, Molina A et al (2003b) Yttium-90 ibritumomab tiutexan radioimmunotherapy (Rit) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) (abstract). Proc Am Soc Clin Oncol 22:597

    Google Scholar 

  • Witzig TE, Flinn IW, Gordon LI et al (2002b) Treatment with ibritumomab-tiutexan in patients with rituximab-refactory follicular non-Hodgkin’s lymphoma. J Clin Oncol 20:3262–3269

    Article  PubMed  CAS  Google Scholar 

  • Witzig TE, Gordon LI, Cabanillas F et al (2002a) Randomized controlled trial of yttrium-90-labeled ibritumomab tiutexan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463

    Article  PubMed  Google Scholar 

  • Wong JY, Shibata S, Williams LE et al (2003) A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 9:5842–5852

    PubMed  CAS  Google Scholar 

  • Zeng ZC, Tang ZY, Liu KD et al (1998) Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131J-anti-HCC mAB. Phase I/II clinical trials. Int J Cancer Res Clin Oncol 124:275–280

    Article  CAS  Google Scholar 

Download references

Authors
  1. B. Wittig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Rieth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Enghofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schwerpunkt Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale

    Hans-Joachim Schmoll (Direktor der Klinik und Poliklinik für Innere Medizin IV) (Direktor der Klinik und Poliklinik für Innere Medizin IV)

  2. Onkologie-Hämatologie-Gastroenterologie-Hepatologie-Infektiologie, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena

    Klaus Höffken (Direktor der Klinik und Poliklinik für Innere Medizin II) (Direktor der Klinik und Poliklinik für Innere Medizin II)

  3. Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité-Campus Mitte Schumannstraße 20/21, 10117, Berlin

    Kurt Possinger (Direktor der Medizinischen Klinik II) (Direktor der Medizinischen Klinik II)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Wittig, B., Rieth, A., Enghofer, E. (2006). Radioimmuntherapie. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_45

Download citation

  • DOI: https://doi.org/10.1007/3-540-31303-6_45

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20657-6

  • Online ISBN: 978-3-540-31303-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation